Drug intelligence / Profile preview

GSK1827771

Development stage: Phase 1
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

GSK1827771 is a monoclonal antibody developed by GSK (formerly GlaxoSmithKline) as an anti-interleukin 1 (IL-1) agent for the treatment of rheumatoid arthritis. It functions as an interleukin 1 receptor antagonist, specifically targeting the IL-1 receptor type I (IL1R1), thereby inhibiting the pro-inflammatory effects mediated by IL-1 signaling. The drug was evaluated in phase I clinical trials for safety and tolerability in healthy volunteers but development was discontinued after phase I without further advancement or approval[1][2][3][4].

Other names: GSK 1827771GSK1827771GSK-1827771

Targets

IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on GSK1827771.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK1827771.

Explore the full profile